Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Bayer A G Ord (OP:BAYZF)

41.50 +1.46 (+3.65%)

Streaming Delayed Price Updated: 3:11 PM EDT, Jun 5, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	2,600
Open	41.50
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	40.04
Today's Range	41.50 - 41.52
52wk Range	29.16 - 58.33
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Phase III FIND‑CKD Results Show Bayer’s KERENDIA® (finerenone) Improved eGFR Slope and Reduced Risk of a Composite Kidney-Cardiovascular Outcome in Adults with Non‑Diabetic Chronic Kidney Disease

June 05, 2026

From Bayer

Via Business Wire

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

June 02, 2026

From Bayer

Via Business Wire

Performance

YTD	-7.6%	-7.6%
1 Month	-8.0%	-8.0%
3 Month	-1.5%	-1.5%
6 Month	+7.2%	+7.2%
1 Year	+37.5%	+37.5%

More News

ASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial

May 30, 2026

From Bayer

Via Business Wire

ASCO 2026: Bayer to Present New Data Across Oncology Portfolio

May 21, 2026

From Bayer

Via Business Wire

Bayer’s KERENDIA® (finerenone) Granted Priority Review of Supplemental New Drug Application by U.S. FDA for Treatment of Adults with Type 1 Diabetes and Chronic Kidney Disease

May 21, 2026

From Bayer

Via Business Wire

Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack

May 19, 2026

From Bayer

Via Business Wire

U.S. FDA Grants Priority Review to Supplemental New Drug Application for HYRNUO® (sevabertinib) Under Investigation as a First-Line Treatment of HER2-Mutated Non-Small Cell Lung Cancer

May 18, 2026

From Bayer

Via Business Wire

AUA 2026: Phase II ARASEC Data Further Supports the Efficacy and Safety of NUBEQA® (darolutamide) Plus ADT in Patients with Metastatic Castration-Sensitive Prostate Cancer

May 15, 2026

From Bayer

Via Business Wire

Bayer Introduces Midol® in Motion, Empowering Menstruators to Find PMS Relief Through Movement

May 15, 2026

From Bayer

Via Business Wire

Bayer Partners with Luke Bryan to Donate 1 Million Meals Through Feeding America® to Expand Access to Food and Nutrition in Rural Communities

May 13, 2026

From Bayer

Via Business Wire

Investigational PET Tracer Iodine 124 Evuzamitide from Bayer Met Primary Endpoints in Phase III Study in Patients Suspected to Have Cardiac Amyloidosis

May 07, 2026

From Bayer

Via Business Wire

Bayer to Acquire Perfuse Therapeutics to Complement Ophthalmology Pipeline

May 06, 2026

From Bayer

Via Business Wire

Bayer to Present 13 Abstracts From Its Stroke Franchise at ESOC 2026, Including Two Late-breaking Analyses From the Phase III OCEANIC-STROKE Trial of Asundexian

April 29, 2026

From Bayer

Via Business Wire

New Study Highlights Societal Optimism Toward Breakthrough Science, and Rising Anxiety About How Fast the World Is Changing

April 29, 2026

From Bayer

Via Business Wire

Bayer Announces Leadership Change Within Pharmaceuticals’ Worldwide Markets Organization in the U.S. to Support Company’s Full Growth Potential

March 31, 2026

From Bayer

Via Business Wire

Multiplatinum Rapper, Actor Ludacris Partners with One A Day® to Help People Realize that Health Does Not Need to Be Ludacris

March 26, 2026

From Bayer

Via Business Wire

KERENDIA® (finerenone) Meets Primary Endpoint in Investigational Phase III FIND-CKD Study in Patients with Non-Diabetic Chronic Kidney Disease

March 16, 2026

From Bayer

Via Business Wire

New FDA 510(k) Clearance Expands Bayer’s MEDRAD® MRXperion MR Injection System Support Across Diverse Range of MR Environments

March 04, 2026

From Bayer

Via Business Wire

Bayer Reports Results for the Investigational Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer

February 27, 2026

From Bayer

Via Business Wire

Bayer’s XOFIGO® (radium-223 dichloride) Plus Enzalutamide Demonstrates Significant Overall Survival Benefit in PEACE-3 Trial in Patients With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases

February 26, 2026

From Bayer

Via Business Wire

Bayer Alleges J&J’s Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J’s ERLEADA

February 23, 2026

From Bayer

Via Business Wire

Bayer® Aspirin Partners with Celebrity Chef Jeff Mauro for Immersive Dark Dining Experience This American Heart Month

February 12, 2026

From Bayer

Via Business Wire

Bayer’s Asundexian Demonstrated a Substantial 26% Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, With No Increase in ISTH Major Bleeding Versus Placebo

February 05, 2026

From Bayer

Via Business Wire

Bayer Teams Up with Former Professional Quarterback Tony Romo on ‘Highlights REAL’ Campaign

January 29, 2026

From Bayer

Via Business Wire

Bayer to Present Results From Phase III OCEANIC-STROKE Study of Asundexian in Secondary Stroke Prevention

January 27, 2026

From Bayer

Via Business Wire

Frequently Asked Questions

Is Bayer A G Ord publicly traded?

Yes, Bayer A G Ord is publicly traded.

What exchange does Bayer A G Ord trade on?

Bayer A G Ord trades on the OTC Traded

What is the ticker symbol for Bayer A G Ord?

The ticker symbol for Bayer A G Ord is BAYZF on the OTC Traded

What is the current price of Bayer A G Ord?

The current price of Bayer A G Ord is 41.50

When was Bayer A G Ord last traded?

The last trade of Bayer A G Ord was at 06/05/26 03:11 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.